Scholarlink

<p>Magnetic hyperthermia therapy (MHT) has emerged as a promising noninvasive approach for tumor treatment. However, the clinical translation of MHT has been significantly hampered by two critical challenges: insufficient magnetothermal conversion efficiency and compromised biosecurity of conventional magnetic nanoparticles. Addressing these limitations, we developed an innovative biomimetic synthesis strategy by engineering cobalt-doped magnetoferritins (PcFn-Co-<i>x</i>) within recombinant hyperthermophilic archaeon ferritin (PcFn) cages at a precisely controlled biomineralization temperature of 90 °C. This breakthrough approach yielded monodisperse PcFn-Co-<i>x</i> nanoparticles with core sizes (13.3–19.6 nm) that remarkably surpass the conventional size limitations of ferritin inner cages. The optimized PcFn-Co- 5 nanoparticles demonstrated unprecedented magnetothermal performance, achieving a record-high specific absorption rate (SAR) of 910 W·g<sup>-1</sup> under biologically safe excitation conditions (33 kA·m<sup>-1</sup> and 150 kHz). Magnetic characterization revealed that the cobalt doping significantly modulates the magnetic energy barrier by enhancing coercivity and magnetic anisotropy, with SAR values showing a remarkable positive correlation with these magnetic parameters. This work presents a novel paradigm for the biomimetic synthesis of high-performance magnetoferritins and pave the way for their clinical application in MHT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Biomimetic mineralization synthesis of cobalt-doped magnetoferritin for enhancing magnetic hyperthermia

  • 期刊论文

  • 发表日期：

    2025年6月9日

查看全文
  • Jiacheng Yu,
  • Yuele Zhang,
  • Yuxin Fang,
  • Yongxin Pan,
  • Changqian Cao

摘要

Magnetic hyperthermia therapy (MHT) has emerged as a promising noninvasive approach for tumor treatment. However, the clinical translation of MHT has been significantly hampered by two critical challenges: insufficient magnetothermal conversion efficiency and compromised biosecurity of conventional magnetic nanoparticles. Addressing these limitations, we developed an innovative biomimetic synthesis strategy by engineering cobalt-doped magnetoferritins (PcFn-Co-x) within recombinant hyperthermophilic archaeon ferritin (PcFn) cages at a precisely controlled biomineralization temperature of 90 °C. This breakthrough approach yielded monodisperse PcFn-Co-x nanoparticles with core sizes (13.3–19.6 nm) that remarkably surpass the conventional size limitations of ferritin inner cages. The optimized PcFn-Co- 5 nanoparticles demonstrated unprecedented magnetothermal performance, achieving a record-high specific absorption rate (SAR) of 910 W·g-1 under biologically safe excitation conditions (33 kA·m-1 and 150 kHz). Magnetic characterization revealed that the cobalt doping significantly modulates the magnetic energy barrier by enhancing coercivity and magnetic anisotropy, with SAR values showing a remarkable positive correlation with these magnetic parameters. This work presents a novel paradigm for the biomimetic synthesis of high-performance magnetoferritins and pave the way for their clinical application in MHT.